MOGS

Across TCGA pan-cancer cohorts, MOGS mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MOGS data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MOGS mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MOGS expression acts as an unfavorable survival marker.

CCRCC, PDAC, and HNSC are the cancer types where MOGS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.202	0.985	.007	17	view →
PDAC	DFS	Quartile	All	0.556	0.903	.004	13	view →
HNSC	OS	Median	All	0.484	1.000	.038	12	view →
LSCC	OS	Median	All	0.802	0.935	.011	3	view →
GBM	DFS	Quartile	All	0.742	0.867	.021	2	view →
UCEC	DFS	Tertile	All	0.780	0.946	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MOGS–CCRCC (OS)

Open the CCRCC breakdown →